Onkologie. 2025:19(4):219-222 | DOI: 10.36290/xon.2025.041

Treatment of patients with myelofibrosis and anemia

Natália Podstavková
Interní hematologická a onkologická klinika, LF MU a FN Brno

Myelofibrosis has the highest symptom burden and frequency of hepatosplenomegaly from all myeloproliferative neoplasms. In addition patients with MF often develop anemia with varying degrees of severity, which can be related to myelofibrosis pathogenesis or develop as a result of therapy with JAK2 inhibitors. Although symptoms can be similar between the two anemia types, only anemia as a result of myelofibrosis itself is negative prognostic factor of reduced overall survival. JAK2 inhibitors differ in their effect on anemia from one another.

Keywords: primary myelofibrosis, secondary myelofibrosis, JAK2 inhibitors, ruxolitinib, momelotinib.

Accepted: September 30, 2025; Published: October 8, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podstavková N. Treatment of patients with myelofibrosis and anemia. Onkologie. 2025;19(4):219-222. doi: 10.36290/xon.2025.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 8.10.2026

    References

    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia. 2022;36(7):1703-1719. Go to original source...
    2. Guijarro-Hernandez A, Vizmanos JL. A broad overview of signaling in Ph-negative classic myeloproliferative neoplasms. Cancers. 2021;13(5):984. Go to original source... Go to PubMed...
    3. Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17): 2635-2642. Go to original source... Go to PubMed...
    4. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. Go to original source... Go to PubMed...
    5. Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136:61-70. Go to original source... Go to PubMed...
    6. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703-1708. Go to original source... Go to PubMed...
    7. Asher S, McLornan DP, Harrison CN. Current and future therapies for myelofibrosis. Blood Rev. 2020;42:100715. Go to original source... Go to PubMed...
    8. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057-1069. Go to original source... Go to PubMed...
    9. Verstovsek S, Manshouri T, Pilling D, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213(9):1723-1740. Go to original source... Go to PubMed...
    10. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25-33. Go to original source... Go to PubMed...
    11. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895-2901. Go to original source... Go to PubMed...
    12. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. Go to original source... Go to PubMed...
    13. Guglielmelli P, Rotunno G, Pacilli A, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918-922. Go to original source... Go to PubMed...
    14. Pardanani A, Finke C, Abdelrahman RA, et al. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88(4):312-316. Go to original source... Go to PubMed...
    15. Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. Hemasphere. 2017;1(1):e1. Go to original source... Go to PubMed...
    16. Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101(12):e482-e484. Go to original source... Go to PubMed...
    17. Harrison CN, McLornan DP. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Hematology Am Soc Hematol Educ Program. 2017;2017(1):489-497. Go to original source... Go to PubMed...
    18. Verstovsek S, Mesa RA, Gotlib J, et al. COMFORT-I Investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488. Go to original source... Go to PubMed...
    19. Verstovsek S, Kiladjian JJ, Vannucchi AM, et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the COMFORT I and II studies. Blood. 2021;138(suppl 1):1505. Go to original source...
    20. Cervantes F, Ross DM, Radinoff A, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 2021;35(12):3455-3465. Go to original source... Go to PubMed...
    21. Gupta V, Griesshammer M, Martino B, et al. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021;62(4):918-926. Go to original source... Go to PubMed...
    22. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl J Med. 2012;366:787-798. Go to original source... Go to PubMed...
    23. Kuykendall A, Shah S, Talati C, et al. Between a rux and a hard place: Evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97:435-441. Go to original source... Go to PubMed...
    24. Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126:1243-1252. Go to original source... Go to PubMed...
    25. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643-651. Go to original source... Go to PubMed...
    26. Verstovsek S, Mesa R, Gupta V, et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023;7(14):3582-3591. Go to original source... Go to PubMed...
    27. Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022;36(9): 2261-2268. Go to original source... Go to PubMed...
    28. Harrison CN, Vannucchi AM, Recher C, et al. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. Adv Ther. 2024;41(9):3722-3735. Go to original source... Go to PubMed...
    29. Singer JW, Al-Fayoumi S, Ma H, et al. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol. 2016;8:11-19. Go to original source... Go to PubMed...
    30. Jarocha DJ, Gadue P, Tong W, et al. Janus Kinase (Jak) 1 Inhibition Affects Both Megakaryopoiesis and Thrombopoiesis. Blood. 2018;132(Supplement 1):2559. Go to original source...
    31. Oh ST, Mesa RA, Harrison CN, Bose P, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023;7(19):5835-5842. Go to original source... Go to PubMed...
    32. Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 2022;15(8):671-684. Go to original source... Go to PubMed...
    33. Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. J Hematol Oncol. 2020;13(1):162. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.